How Should Patients with Recurrent Disease Be Treated Actually?
作者： Anja Lorch
DOI: 10.1007/978-3-319-17467-9_7
关键词: Clinical Practice 、 Salvage therapy 、 Medicine 、 Recurrent disease 、 Oncology 、 Carboplatin 、 Risk profile 、 In patient 、 Etoposide 、 Chemotherapy 、 Internal medicine
摘要: It was the unsatisfactory results of conventional-dose chemotherapy at time relapse, that led to HDCT being introduced into clinical practice. Even today, combination carboplatin and etoposide (CE) remains mainstay all salvage regimens with HDCT. The use has resulted in long-term remission achieved even patients unfavorable prognoses or multiple relapses. What controversial, however, is role as first-line therapy relapsed highly favorable risk profiles. In order avoid overtreatment, should only be administered specialist centres necessary expertise.
springer.com
sci-hub.st 参考文章(19)
, Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy Journal of Clinical Oncology. ,vol. 28, pp. 4906- 4911 ,(2010) , 10.1200/JCO.2009.26.8128
Robert J. Motzer, Madhu Mazumdar, Joel Sheinfeld, Dean F. Bajorin, Homer A. Macapinlac, Manjit Bains, Lilian Reich, Carlos Flombaum, Tania Mariani, William P. Tong, George J. Bosl, Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients Journal of Clinical Oncology. ,vol. 18, pp. 1173- 1180 ,(2000) , 10.1200/JCO.2000.18.6.1173
Craig R Nichols, Guido Tricot, Stephen D Williams, Koen van Besien, Patrick J Loehrer, Bruce J Roth, Luke Akard, Ron Hoffman, Robert Goulet, Steven N Wolff, None, Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. Journal of Clinical Oncology. ,vol. 7, pp. 932- 939 ,(1989) , 10.1200/JCO.1989.7.7.932
J Beyer, N Schwella, J Zingsem, I Strohscheer, I Schwaner, H Oettle, S Serke, D Huhn, W Stieger, Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. Journal of Clinical Oncology. ,vol. 13, pp. 1328- 1335 ,(1995) , 10.1200/JCO.1995.13.6.1328
C. Sammler, J. Beyer, C. Bokemeyer, J.T. Hartmann, O. Rick, Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: Evaluation of a prognostic score for survival after high-dose chemotherapy European Journal of Cancer. ,vol. 44, pp. 237- 243 ,(2008) , 10.1016/J.EJCA.2007.10.025
G. Varuni Kondagunta, Jennifer Bacik, Joel Sheinfeld, Dean Bajorin, Manjit Bains, Lillian Reich, John Deluca, Amy Budnick, Nicole Ishill, Madhu Mazumdar, George J. Bosl, Robert J. Motzer, Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors Journal of Clinical Oncology. ,vol. 25, pp. 85- 90 ,(2006) , 10.1200/JCO.2006.06.9401
Lawrence H Einhorn, Stephen D Williams, Amy Chamness, Mary J Brames, Susan M Perkins, Rafat Abonour, None, High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors The New England Journal of Medicine. ,vol. 357, pp. 340- 348 ,(2007) , 10.1056/NEJMOA067749
G. Varuni Kondagunta, Robert J. Motzer, Chemotherapy for advanced germ cell tumors. Journal of Clinical Oncology. ,vol. 24, pp. 5493- 5502 ,(2006) , 10.1200/JCO.2006.08.7882
J. Beyer, P. Albers, R. Altena, J. Aparicio, C. Bokemeyer, J. Busch, R. Cathomas, E. Cavallin-Stahl, N.W. Clarke, J. Claßen, G. Cohn-Cedermark, A.A. Dahl, G. Daugaard, U. De Giorgi, M. De Santis, M. De Wit, R. De Wit, K.P. Dieckmann, M. Fenner, K. Fizazi, A. Flechon, S.D. Fossa, J.R. Germá Lluch, J.A. Gietema, S. Gillessen, A. Giwercman, J.T. Hartmann, A. Heidenreich, M. Hentrich, F. Honecker, A. Horwich, R.A. Huddart, S. Kliesch, C. Kollmannsberger, S. Krege, M.P. Laguna, L.H.J. Looijenga, A. Lorch, J.P. Lotz, F. Mayer, A. Necchi, N. Nicolai, J. Nuver, K. Oechsle, J. Oldenburg, J.W. Oosterhuis, T. Powles, E. Rajpert-De Meyts, O. Rick, G. Rosti, R. Salvioni, M. Schrader, S. Schweyer, F. Sedlmayer, A. Sohaib, R. Souchon, T. Tandstad, C. Winter, C. Wittekind, Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer Annals of Oncology. ,vol. 24, pp. 878- 888 ,(2013) , 10.1093/ANNONC/MDS579
A. Lorch, A. Neubauer, M. Hackenthal, A. Dieing, J.T. Hartmann, O. Rick, C. Bokemeyer, J. Beyer, High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors Annals of Oncology. ,vol. 21, pp. 820- 825 ,(2010) , 10.1093/ANNONC/MDP366